DK1293207T3 - Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS - Google Patents

Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS

Info

Publication number: DK1293207T3
Authority: DK; Denmark
Prior art keywords: ritonavir; abt; cytochrome; pharmacokinetics; improve
Prior art date: 1995-06-29

Application number

DK02079004T

Other languages

English (en)

Inventor

Daniel W Norbeck

Dales J Kempf

John M Leonard

Richard J Bertz

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-29

Filing date

1996-06-28

Publication date

2009-10-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26667933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1293207(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-06-28 Application filed by Abbott Lab filed Critical Abbott Lab

2009-10-05 Application granted granted Critical

2009-10-05 Publication of DK1293207T3 publication Critical patent/DK1293207T3/da

Links

NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 title abstract 3
229960000311 ritonavir Drugs 0.000 title abstract 3
208000030507 AIDS Diseases 0.000 title abstract 2
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 title abstract 2
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
208000031886 HIV Infections Diseases 0.000 abstract 1
208000037357 HIV infectious disease Diseases 0.000 abstract 1
229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
239000004030 hiv protease inhibitor Substances 0.000 abstract 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Epoxy Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Saccharide Compounds (AREA)

DK02079004T 1995-06-29 1996-06-28 Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS DK1293207T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65495P	1995-06-29	1995-06-29
US384995P	1995-09-15	1995-09-15
PCT/US1996/011015 WO1997001349A1 (en)	1995-06-29	1996-06-28	Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids

Publications (1)

Publication Number	Publication Date
DK1293207T3 true DK1293207T3 (da)	2009-10-05

Family

ID=26667933

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK96922604T DK0871465T3 (da)	1995-06-29	1996-06-28	Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS
DK02079004T DK1293207T3 (da)	1995-06-29	1996-06-28	Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS
DK10185624.3T DK2295052T3 (da)	1995-06-29	1996-06-28	Anvendelse af ritonavir til forbedring af farmakokinetikken af lægemidler, der metaboliseres af cytochrom P450
DK02079003T DK1284140T3 (da)	1995-06-29	1996-06-28	Anvendelse af ritonavir (ABT-538) til forbedring af farmakokinetikken hos lægemidler, der metaboliseres af cytochrom P450, ved en metode til behandling af AIDS

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK96922604T DK0871465T3 (da)	1995-06-29	1996-06-28	Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK10185624.3T DK2295052T3 (da)	1995-06-29	1996-06-28	Anvendelse af ritonavir til forbedring af farmakokinetikken af lægemidler, der metaboliseres af cytochrom P450
DK02079003T DK1284140T3 (da)	1995-06-29	1996-06-28	Anvendelse af ritonavir (ABT-538) til forbedring af farmakokinetikken hos lægemidler, der metaboliseres af cytochrom P450, ved en metode til behandling af AIDS

Country Status (14)

Country	Link
US (2)	US6037157A (da)
EP (7)	EP1273298A3 (da)
JP (4)	JP4023823B2 (da)
KR (2)	KR100824547B1 (da)
AT (2)	ATE225186T1 (da)
AU (1)	AU722812B2 (da)
CA (1)	CA2224738C (da)
DE (3)	DE69637511T2 (da)
DK (4)	DK0871465T3 (da)
ES (4)	ES2304416T3 (da)
HK (1)	HK1049103A1 (da)
IL (1)	IL122546A (da)
PT (4)	PT1293207E (da)
WO (1)	WO1997001349A1 (da)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3657002B2 (ja)	1992-08-25	2005-06-08	ジー．ディー．サールアンドカンパニー	レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド
US7141609B2 (en)	1992-08-25	2006-11-28	G.D. Searle & Co.	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
UA49803C2 (uk) *	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій
US6037157A (en) *	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
US5750493A (en) *	1995-08-30	1998-05-12	Raymond F. Schinazi	Method to improve the biological and antiviral activity of protease inhibitors
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
CZ298749B6 (cs) *	1996-10-18	2008-01-16	Vertex Pharmaceuticals Incorporated	Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
WO1998020888A1 (en) *	1996-11-08	1998-05-22	Japan Energy Corporation	Aids remedy
ZA9710071B (en) *	1996-11-21	1998-05-25	Abbott Lab	Pharmaceutical composition.
US6232333B1 (en)	1996-11-21	2001-05-15	Abbott Laboratories	Pharmaceutical composition
KR19990016003A (ko) *	1997-08-12	1999-03-05	성재갑	치토크롬 저해제 조성물
KR100348561B1 (ko) *	1997-08-12	2002-09-18	주식회사 엘지씨아이	Lb71350과 dmp450을 함유하는 조성물
KR19990016002A (ko) *	1997-08-12	1999-03-05	성재갑	Ｌｂ71350을 함유하는 치토크롬 ｐ450 기질
US6180634B1 (en)	1997-11-13	2001-01-30	Merck & Co., Inc.	Combination therapy for the treatment of AIDS
JP4776775B2 (ja)	1998-06-23	2011-09-21	アメリカ合衆国	Ｈｉｖ感染哺乳動物を治療するための医薬組成物
MY145265A (en) *	1998-07-20	2012-01-13	Abbott Lab	Amorphous ritonavir
US6894171B1 (en)	1998-07-20	2005-05-17	Abbott Laboratories	Polymorph of a pharmaceutical
EP1712231A3 (en) *	1998-11-04	2007-11-21	Pharmacia & Upjohn Company LLC	Method for improving the pharmacokinetics of tipranavir
CN1154491C (zh) *	1998-11-04	2004-06-23	法玛西雅厄普约翰美国公司	用于改善替普拉那维的药物动力学的方法
US7141593B1 (en)	1999-06-04	2006-11-28	Abbott Laboratories	Pharmaceutical formulations
WO2000074677A2 (en) *	1999-06-04	2000-12-14	Abbott Laboratories	Improved pharmaceutical formulations
WO2001034119A2 (en) *	1999-11-12	2001-05-17	Abbott Laboratories	Inhibitors of crystallization in a solid dispersion
US7364752B1 (en)	1999-11-12	2008-04-29	Abbott Laboratories	Solid dispersion pharamaceutical formulations
EP1248600B1 (en) *	2000-01-19	2008-05-14	Abbott Laboratories	Improved hiv protease inhibitors pharmaceutical formulations
DE10026698A1 (de) *	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR037797A1 (es) *	2001-12-12	2004-12-01	Tibotec Pharm Ltd	Combinacion de inhibidores de proteasa dependientes del citocromo p450
IL163666A0 (en)	2002-02-22	2005-12-18	New River Pharmaceuticals Inc	Active agent delivery systems and methods for protecting and administering active agents
US7205413B2 (en) *	2002-05-03	2007-04-17	Transform Pharmaceuticals, Inc.	Solvates and polymorphs of ritonavir and methods of making and using the same
US20040152625A1 (en) *	2002-12-16	2004-08-05	Boehringer Ingelheim International Gmbh	Method for improving the pharmacokinetics of an NNRTI
US7320961B2 (en)	2003-03-24	2008-01-22	Abbott Laboratories	Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US8377952B2 (en) *	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
PE20050374A1 (es) *	2003-09-05	2005-05-30	Vertex Pharma	Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
EP1670415A4 (en) *	2003-09-12	2007-12-05	Vertex Pharma	ANIMAL MODEL FOR STUDYING PROTEASES ACTIVITY AND HEPATIC DISORDERS
CA2541634A1 (en)	2003-10-10	2005-04-28	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1944042A1 (en)	2003-10-27	2008-07-16	Vertex Pharmceuticals Incorporated	Combinations for HCV treatment
JP4890254B2 (ja) *	2003-10-27	2012-03-07	バーテックスファーマシューティカルズインコーポレイテッド	Ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ耐性突然変異体
KR20060127939A (ko) *	2004-01-30	2006-12-13	화이자 인코포레이티드	Ｈｉｖ 프로테아제 억제제 및 사이토크롬 ｐ450 효소 활성억제제를 포함하는 조성물
EP2311851A3 (en)	2004-02-04	2011-05-25	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7388008B2 (en) *	2004-08-02	2008-06-17	Ambrilia Biopharma Inc.	Lysine based compounds
CA2583472A1 (en) *	2004-10-01	2006-04-13	Chao Lin	Hcv ns3-ns4a protease inhibition
MY141025A (en)	2004-10-29	2010-02-25	Vertex Pharma	Dose forms
CA2583195A1 (en) *	2004-11-19	2006-05-26	Boehringer Ingelheim International Gmbh	Method for treating hiv infection through co-administration of tipranavir and reverset
CA2586231A1 (en) *	2004-11-19	2006-05-26	Boehringer Ingelheim International Gmbh	Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
EP1819335A1 (en) *	2004-12-01	2007-08-22	Boehringer Ingelheim International Gmbh	Method for treating hiv infection through co-administration of tipranavir and sch-417690
US20060142344A1 (en) *	2004-12-01	2006-06-29	Boehringer Ingelheim International Gmbh	Method for treating HIV infection through co-administration of tipranavir and GW695634
US7786153B2 (en)	2005-03-02	2010-08-31	Abbott Laboratories Inc.	Compounds that are useful for improving pharmacokinetics
US20060222627A1 (en) *	2005-03-30	2006-10-05	Andrew Carter	Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
AR053845A1 (es) *	2005-04-15	2007-05-23	Tibotec Pharm Ltd	5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
CA2606025A1 (en) *	2005-04-27	2006-11-02	Ambrilia Biopharma Inc.	Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
JO2768B1 (en)	2005-07-29	2014-03-15	تيبوتيك فارماسيوتيكالز ليمتد	Large cyclic inhibitors of hepatitis C virus
US20100120855A1 (en) *	2005-07-29	2010-05-13	Tibotec Pharmaceuticals Ltd.	Macrocylic inhibitors of hepatitis c virus
DK1919899T3 (da) *	2005-07-29	2011-08-01	Tibotec Pharm Ltd	Makrocykliske inhibitorer af hepatitis C virus
ES2373685T3 (es) *	2005-07-29	2012-02-07	Tibotec Pharmaceuticals	Inhibidores macrocíclicos del virus de la hepatitis c.
DK1919904T3 (da) *	2005-07-29	2014-04-07	Janssen R & D Ireland	Makrocykliske inhibitorer af hepatitis-c-virus
PL1919898T3 (pl) *	2005-07-29	2011-06-30	Tibotec Pharm Ltd	Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
PE20070210A1 (es)	2005-07-29	2007-04-16	Tibotec Pharm Ltd	Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
TWI412535B (zh) *	2005-07-29	2013-10-21	Tibotec Pharm Ltd	Ｃ型肝炎病毒之大環抑制劑（五）
CA2617679A1 (en) *	2005-08-02	2007-02-08	Steve Lyons	Inhibitors of serine proteases
US7964624B1 (en) *	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
AR055395A1 (es)	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7705138B2 (en)	2005-11-11	2010-04-27	Vertex Pharmaceuticals Incorporated	Hepatitis C virus variants
AU2006315438A1 (en)	2005-11-11	2007-05-24	Vertex Pharmaceuticals Incorporated	Hepatitis C virus variants
US8227450B2 (en) *	2005-11-30	2012-07-24	Ambrilia Biopharma Inc.	Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
US7910595B2 (en) *	2005-12-21	2011-03-22	Abbott Laboratories	Anti-viral compounds
CN102702194A (zh)	2005-12-21	2012-10-03	雅培制药有限公司	抗病毒化合物
US7915411B2 (en) *	2005-12-21	2011-03-29	Abbott Laboratories	Anti-viral compounds
EP2345652A1 (en)	2005-12-21	2011-07-20	Abbott Laboratories	Antiviral compounds
BRPI0620865A2 (pt)	2005-12-30	2011-11-29	Gilead Sciences Inc	métodos para melhorar a farmacocinética de inibidores das integrases do hiv
US20090233964A1 (en) *	2005-12-30	2009-09-17	Gilead Sciences, Inc.	Methods for improving the pharmacokinetics of hiv integrase inhibitors
CA2643688A1 (en)	2006-02-27	2007-08-30	Vertex Pharmaceuticals Incorporated	Co-crystals and pharmaceutical compositions comprising the same
CA2645684A1 (en) *	2006-03-06	2007-09-13	Abbott Laboratories	Compositions and methods of use of ritonavir for treating hcv
WO2007109080A2 (en)	2006-03-16	2007-09-27	Vertex Pharmaceuticals Incorporated	Deuterated hepatitis c protease inhibitors
JP2009530382A (ja) *	2006-03-23	2009-08-27	シェーリングコーポレイション	Ｈｃｖプロテアーゼインヒビターとｃｙｐ３ａ４インヒビターとの組み合わせ、および関連する処置方法
CA2643680A1 (en)	2006-04-11	2007-11-22	Novartis Ag	Hcv/hiv inhibitors and their uses
US9526769B2 (en)	2006-06-06	2016-12-27	Enanta Pharmaceuticals, Inc.	Macrocylic oximyl hepatitis C protease inhibitors
US8268776B2 (en)	2006-06-06	2012-09-18	Enanta Pharmaceuticals, Inc.	Macrocylic oximyl hepatitis C protease inhibitors
SI2049506T2 (sl) *	2006-07-07	2024-07-31	Gilead Sciences, Inc.	Modulatorji farmakokinetičnih lastnosti terapevtikov
NO347119B1 (no) *	2006-07-07	2023-05-15	Gilead Sciences Inc	Modulatorer av farmakokinetikkegenskaper til terapeutika
EP2465855A1 (en)	2006-08-31	2012-06-20	Abbott Laboratories	Cytochrome P450 oxidase inhibitors and uses thereof
AU2007337830A1 (en)	2006-09-21	2008-07-03	Ambrilia Biopharma Inc.	Benzenesulfonamide derivatives as HIV protease inhibitors
CA2669938C (en)	2006-11-15	2016-01-05	Abbott Laboratories	Solid pharmaceutical dosage formulations
CA2661338C (en)	2006-11-17	2015-05-12	Tibotec Pharmaceuticals Ltd.	Macrocyclic inhibitors of hepatitis c virus
US8937080B2 (en) *	2007-02-08	2015-01-20	Medivir Ab	Pyrimidine substituted macrocyclic HCV inhibitors
SI2487163T1 (sl) *	2007-02-23	2016-12-30	Gilead Sciences, Inc.	Modulatorji farmakokinetičnih lastnosti terapevtskih sredstev
EP4403221A3 (en) *	2007-02-23	2024-10-09	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
GEP20125645B (en) *	2007-02-27	2012-09-25	Vertex Pharma	Co-crystals and pharmaceutical compositions comprising the same
WO2008106058A2 (en) *	2007-02-27	2008-09-04	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
ES2381410T3 (es)	2007-05-04	2012-05-28	Vertex Pharmceuticals Incorporated	Terapia de combinación paa el tratamiento de infecciones por VHC
JP2010530889A (ja) *	2007-06-22	2010-09-16	ブリストル−マイヤーズスクイブカンパニー	アタザナビルを含む錠剤組成物
ES2359770T3 (es) *	2007-06-22	2011-05-26	Bristol-Myers Squibb Company	Composiciones en comprimidos que contienen atazanavir.
JP2010530892A (ja) *	2007-06-22	2010-09-16	ブリストル−マイヤーズスクイブカンパニー	アタザナビルを含む錠剤組成物
SI2170292T1 (sl) *	2007-06-22	2014-05-30	Bristol-Myers Squibb Holdings Ireland	Tabletirani sestavki, ki vsebujejo atazanavir
CN101796040A (zh) *	2007-07-06	2010-08-04	吉里德科学公司	治疗剂的药代动力学特性调节剂
WO2009032198A1 (en) *	2007-08-30	2009-03-12	Vertex Pharmaceuticals Incorporated	Co-crystals and pharmaceutical compositions comprising the same
EP2214668A1 (en) *	2007-10-29	2010-08-11	Cipla Limited	Novel antiretroviral combination
WO2009070692A1 (en) *	2007-11-29	2009-06-04	Enanta Pharmaceuticals, Inc.	C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
US8030307B2 (en) *	2007-11-29	2011-10-04	Enanta Pharmaceuticals, Inc.	Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
UA103013C2 (uk) *	2007-12-06	2013-09-10	Тиботек Фармасьютикелз	Амідні сполуки як активатори противірусних препаратів
GT200800303A (es)	2007-12-24	2009-09-18		Combinacion anti-retroviral
PT2231628E (pt)	2008-01-04	2015-12-29	Gilead Sciences Inc	Inibidores de citocromo p450
CN101959506A (zh) *	2008-02-28	2011-01-26	雅培制药有限公司	片剂和其制备方法
US20090318561A1 (en) *	2008-06-23	2009-12-24	Mutual Pharmaceutical Company, Inc.	Colchicine products, method of manufacture, and methods of use
TW201012814A (en)	2008-07-01	2010-04-01	Centocor Ortho Biotech Products L P	Cyclopropyl polymerase inhibitors
TWI454476B (zh)	2008-07-08	2014-10-01	Tibotec Pharm Ltd	用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
US8664391B2 (en) *	2008-10-07	2014-03-04	Janssen R&D Ireland Ltd	Amide compounds as boosters of antivirals
US20100137235A1 (en) *	2008-10-15	2010-06-03	Mutual Pharmaceutical Company, Inc.	Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
WO2010070611A1 (en)	2008-12-18	2010-06-24	Ranbaxy Laboratories Limited	Atazanavir formulations
WO2010075376A2 (en)	2008-12-23	2010-07-01	Abbott Laboratories	Anti-viral compounds
WO2010075380A1 (en)	2008-12-23	2010-07-01	Abbott Laboratories	Anti-viral compounds
US8321151B2 (en)	2008-12-30	2012-11-27	The Invention Science Fund I, Llc	Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8315815B2 (en)	2008-12-30	2012-11-20	The Invention Science Fund I, Llc	Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8073633B2 (en) *	2008-12-30	2011-12-06	The Invention Science Fund I, Llc	Computational methods and systems for suggesting modulators of CYP450 as treatment options
WO2010077061A2 (ko) *	2008-12-31	2010-07-08	한올바이오파마 주식회사	항바이러스성 약물을 포함하는 약제학적 제제
US7820681B1 (en) *	2009-01-14	2010-10-26	Mutual Pharmaceutical Company, Inc.	Methods for concomitant administration of colchicine and a second active agent
US8921415B2 (en)	2009-01-29	2014-12-30	Mapi Pharma Ltd.	Polymorphs of darunavir
EP2396028A2 (en)	2009-02-12	2011-12-21	Vertex Pharmceuticals Incorporated	Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
US20100261731A1 (en) *	2009-04-13	2010-10-14	Abbott Laboratories	Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate
EP2419404B1 (en) *	2009-04-15	2015-11-04	AbbVie Inc.	Anti-viral compounds
MY169734A (en) *	2009-04-25	2019-05-14	Hoffmann La Roche	Methods for improving pharmacokinetics
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
US8716454B2 (en)	2009-06-11	2014-05-06	Abbvie Inc.	Solid compositions
EA020031B1 (ru) *	2009-06-11	2014-08-29	Эббви Бахамаз Лтд.	Противовирусные соединения
US8232246B2 (en) *	2009-06-30	2012-07-31	Abbott Laboratories	Anti-viral compounds
US20110034489A1 (en) *	2009-07-31	2011-02-10	Ranbaxy Laboratories Limited	Solid dosage forms of hiv protease inhibitors
WO2011013110A1 (en)	2009-07-31	2011-02-03	Ranbaxy Laboratories Limited	Unit dosage forms of hiv protease inhibitors
US20110046227A1 (en) *	2009-08-21	2011-02-24	Mutual Pharmaceutical Company, Inc.	Methods for concomitant administration of colchicine and a second active agent
EP2528923B1 (en)	2010-01-28	2014-07-30	Mapi Pharma Limited	Process for the preparation of darunavir and darunavir intermediates
CN102844030A (zh)	2010-01-29	2012-12-26	沃泰克斯药物股份有限公司	用于治疗丙型肝炎病毒感染的疗法
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
WO2012015712A1 (en) *	2010-07-30	2012-02-02	Schering Corporation	Inhibition of cyp3a drug metabolism
EP2624826B1 (en)	2010-10-08	2018-07-18	Novartis AG	Vitamin e formulations of sulfamide ns3 inhibitors
JP5906253B2 (ja)	2010-12-16	2016-04-20	アッヴィ・インコーポレイテッド	抗ウイルス性化合物
MX2013006828A (es)	2010-12-16	2014-10-14	Abbvie Inc	Compuestos antivirales.
WO2012109646A1 (en)	2011-02-11	2012-08-16	Vertex Pharmaceuticals Incorporated	Treatment of hcv in hiv infection patients
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
WO2012164575A2 (en)	2011-05-27	2012-12-06	Hetero Research Foundation	Amorphous ritonavir co-precipitated
WO2013080148A1 (en)	2011-11-28	2013-06-06	Ranbaxy Laboratories Limited	A process for the preparation of solid dispersion of lopinavir and ritonavir
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
KR20150046083A (ko) *	2012-08-31	2015-04-29	얀센 파마슈티칼즈, 인코포레이티드	Ｈｃｖ의 거대환형 프로테아제 저해제, 비뉴클레오시드계 ｈｃｖ 저해제 및 리토나비르의 조합물
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
HK1220390A1 (zh)	2013-08-29	2017-05-05	Teva Pharmaceutical Industries Ltd.	包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
UA117375C2 (uk)	2013-09-04	2018-07-25	Медівір Аб	Інгібітори полімерази hcv
EP3057976A1 (en)	2013-10-17	2016-08-24	Medivir Ab	Hcv polymerase inhibitors
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
WO2015125082A1 (en)	2014-02-21	2015-08-27	Mylan Laboratories Limited	Improved process for the preparation of ritonavir
EP3129009A1 (en)	2014-04-08	2017-02-15	Teva Pharmaceutical Industries Ltd	Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
US10076512B2 (en)	2014-05-01	2018-09-18	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US10835496B2 (en)	2015-04-21	2020-11-17	Eiger Biopharmaceuticals, Inc.	Pharmaceutical compositions comprising lonafarnib and ritonavir
WO2022013684A1 (en)	2020-07-11	2022-01-20	Pfizer Inc.	Antiviral heteroaryl ketone derivatives
US11351149B2 (en)	2020-09-03	2022-06-07	Pfizer Inc.	Nitrile-containing antiviral compounds
US11648300B1 (en) *	2022-03-31	2023-05-16	Asavi Llc	Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US384995A (en)		1888-06-26		moore
US5142056A (en)	1989-05-23	1992-08-25	Abbott Laboratories	Retroviral protease inhibiting compounds
USH1649H (en) *	1987-07-31	1997-05-06	Barrish; Joel C.	HIV protease inhibitor combinations
US5354866A (en)	1989-05-23	1994-10-11	Abbott Laboratories	Retroviral protease inhibiting compounds
US5539122A (en) *	1989-05-23	1996-07-23	Abbott Laboratories	Retroviral protease inhibiting compounds
GB8927913D0 (en)	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
ATE296624T1 (de)	1990-11-19	2005-06-15	Monsanto Co	Retrovirusprotease inhibitoren
EP0532466A3 (en)	1991-09-12	1993-06-16	Ciba-Geigy Ag	Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
HU221816B1 (hu)	1991-10-11	2003-01-28	Bristol-Myers Squibb Pharma Company	Gyűrűs karbonil vegyületek, és ezeket tartalmazó gyógyászati készítmények
CA2081970C (en)	1991-11-08	1997-07-08	Joseph P. Vacca	Hiv protease inhibitors useful for the treatment of aids
US5413999A (en)	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
ES2066623T3 (es)	1992-03-13	1995-03-01	Bio Mega Boehringer Ingelheim	Derivados sustituidos del acido pipecolinico como inhibidores de la vih-proteasa.
EP0574135B1 (en)	1992-05-13	1998-11-18	Japan Energy Corporation	Process for producing peptide derivatives and salts thereof
AU4253193A (en)	1992-05-20	1993-12-13	G.D. Searle & Co.	Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors
US5559256A (en)	1992-07-20	1996-09-24	E. R. Squibb & Sons, Inc.	Aminediol protease inhibitors
IS2334B (is)	1992-09-08	2008-02-15	Vertex Pharmaceuticals Inc., (A Massachusetts Corporation)	Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en)	1993-10-07	1996-01-16	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
DE69305093T2 (de) *	1992-12-29	1997-04-17	Abbott Lab	Inhibitoren der retroviralen protease
IL108459A0 (en)	1993-02-05	1994-04-12	Opjohn Company	4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
EP0618222A3 (en)	1993-03-11	1997-01-02	Ciba Geigy Ag	Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid.
AU676299B2 (en) *	1993-06-28	1997-03-06	Akira Fujishima	Photocatalyst composite and process for producing the same
AU7669794A (en)	1993-08-24	1995-03-21	G.D. Searle & Co.	Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
IL110752A (en)	1993-09-13	2000-07-26	Abbott Lab	Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en)	1993-10-01	1996-09-24	Abbott Laboratories	Pharmaceutical composition
WO1995010281A1 (en)	1993-10-13	1995-04-20	Merck & Co., Inc.	Combination therapy for hiv infection
US5491253A (en)	1993-10-22	1996-02-13	Abbott Laboratories	Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
AU7843394A (en) *	1993-10-27	1995-05-22	Regents Of The University Of California, The	Antiviral compounds
KR0125117B1 (ko)	1994-06-15	1997-12-05	성재갑	항 에이즈(aids)효과를 갖는 신규한 인간 면역 결핍 바이러스(hiv)프로테아제 억제 화합물 및 그의 제조방법
IL111991A (en)	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
UA49803C2 (uk) *	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій
IL114808A (en) *	1994-08-11	1999-10-28	Merck & Co Inc	Combinations of protease inhibitors for the treatment of hiv infection and aids
GB9509321D0 (en) *	1995-05-09	1995-06-28	Zylepsis Ltd	Methods of and substances for inhibiting oxidative enzymes
US5567823A (en)	1995-06-06	1996-10-22	Abbott Laboratories	Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) *	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
EP0987853A1 (en)	1998-09-17	2000-03-22	STMicroelectronics S.r.l.	A fully digital phase aligner
TWI519686B (zh)	2005-12-15	2016-02-01	聖戈班晶體探測器公司	低差排密度氮化鎵（ＧａＮ）之生長方法
US8402690B2 (en)	2010-09-09	2013-03-26	Sterling International Inc.	Bedbug trap

1996
- 1996-06-26 US US08/687,774 patent/US6037157A/en not_active Expired - Lifetime
- 1996-06-28 WO PCT/US1996/011015 patent/WO1997001349A1/en not_active Ceased
- 1996-06-28 EP EP02079002A patent/EP1273298A3/en not_active Withdrawn
- 1996-06-28 CA CA002224738A patent/CA2224738C/en not_active Expired - Lifetime
- 1996-06-28 PT PT02079004T patent/PT1293207E/pt unknown
- 1996-06-28 EP EP02079004A patent/EP1293207B1/en not_active Revoked
- 1996-06-28 ES ES02079003T patent/ES2304416T3/es not_active Expired - Lifetime
- 1996-06-28 DE DE69637511T patent/DE69637511T2/de not_active Expired - Lifetime
- 1996-06-28 DE DE69637976T patent/DE69637976D1/de not_active Expired - Lifetime
- 1996-06-28 EP EP01204308A patent/EP1210941A3/en not_active Withdrawn
- 1996-06-28 ES ES96922604T patent/ES2186787T3/es not_active Expired - Lifetime
- 1996-06-28 PT PT96922604T patent/PT871465E/pt unknown
- 1996-06-28 AU AU63420/96A patent/AU722812B2/en not_active Expired
- 1996-06-28 DK DK96922604T patent/DK0871465T3/da active
- 1996-06-28 DK DK02079004T patent/DK1293207T3/da active
- 1996-06-28 KR KR1019970709723A patent/KR100824547B1/ko not_active Expired - Lifetime
- 1996-06-28 EP EP10185624.3A patent/EP2295052B1/en not_active Expired - Lifetime
- 1996-06-28 AT AT96922604T patent/ATE225186T1/de active
- 1996-06-28 ES ES02079004T patent/ES2328559T3/es not_active Expired - Lifetime
- 1996-06-28 EP EP02079003A patent/EP1284140B1/en not_active Revoked
- 1996-06-28 ES ES10185624.3T patent/ES2441736T3/es not_active Expired - Lifetime
- 1996-06-28 PT PT02079003T patent/PT1284140E/pt unknown
- 1996-06-28 JP JP50457297A patent/JP4023823B2/ja not_active Expired - Lifetime
- 1996-06-28 DK DK10185624.3T patent/DK2295052T3/da active
- 1996-06-28 DK DK02079003T patent/DK1284140T3/da active
- 1996-06-28 KR KR1020077028582A patent/KR20070120619A/ko not_active Ceased
- 1996-06-28 DE DE69624136T patent/DE69624136T2/de not_active Expired - Lifetime
- 1996-06-28 AT AT02079003T patent/ATE392895T1/de active
- 1996-06-28 IL IL122546A patent/IL122546A/en active IP Right Grant
- 1996-06-28 EP EP96922604A patent/EP0871465B1/en not_active Expired - Lifetime
- 1996-06-28 EP EP09166053A patent/EP2130534A1/en not_active Ceased
- 1996-06-28 PT PT101856243T patent/PT2295052E/pt unknown
1999
- 1999-04-07 HK HK02108872.4A patent/HK1049103A1/en unknown
2001
- 2001-09-20 US US09/957,171 patent/US6703403B2/en not_active Expired - Lifetime
2007
- 2007-07-02 JP JP2007173713A patent/JP5364871B2/ja not_active Expired - Lifetime
2012
- 2012-02-03 JP JP2012022128A patent/JP2012111775A/ja not_active Withdrawn
2014
- 2014-08-27 JP JP2014172543A patent/JP2015013878A/ja active Pending

Also Published As

Publication number	Publication date
WO1997001349A1 (en)	1997-01-16
DK1284140T3 (da)	2008-08-18
US6703403B2 (en)	2004-03-09
DK2295052T3 (da)	2014-01-20
ATE225186T1 (de)	2002-10-15
EP1210941A2 (en)	2002-06-05
KR100824547B1 (ko)	2008-11-04
EP1284140B1 (en)	2008-04-23
DE69637976D1 (de)	2009-09-03
EP1284140A3 (en)	2003-03-19
EP1293207A1 (en)	2003-03-19
ES2441736T3 (es)	2014-02-06
DE69637511T2 (de)	2009-06-04
IL122546A (en)	2012-01-31
CA2224738A1 (en)	1997-01-16
EP2130534A1 (en)	2009-12-09
PT871465E (pt)	2003-02-28
JP4023823B2 (ja)	2007-12-19
MX9710403A (es)	1998-07-31
IL122546A0 (en)	1998-06-15
EP1284140A2 (en)	2003-02-19
ES2304416T3 (es)	2008-10-16
US20020039998A1 (en)	2002-04-04
EP0871465A1 (en)	1998-10-21
CA2224738C (en)	2002-08-27
KR20070120619A (ko)	2007-12-24
AU722812B2 (en)	2000-08-10
EP2295052B1 (en)	2014-01-08
AU6342096A (en)	1997-01-30
HK1053783A1 (en)	2003-11-07
PT1284140E (pt)	2008-05-14
EP1293207B1 (en)	2009-07-22
JP2007291131A (ja)	2007-11-08
EP1273298A3 (en)	2003-03-19
EP0871465B1 (en)	2002-10-02
HK1016088A1 (en)	1999-10-29
JPH11508884A (ja)	1999-08-03
DE69637511D1 (de)	2008-06-05
ES2186787T3 (es)	2003-05-16
PT2295052E (pt)	2014-01-23
ATE392895T1 (de)	2008-05-15
JP2012111775A (ja)	2012-06-14
JP2015013878A (ja)	2015-01-22
DE69624136T2 (de)	2003-08-14
PT1293207E (pt)	2009-08-11
DE69624136D1 (de)	2002-11-07
ES2328559T3 (es)	2009-11-16
EP2295052A1 (en)	2011-03-16
KR19990028407A (ko)	1999-04-15
JP5364871B2 (ja)	2013-12-11
US6037157A (en)	2000-03-14
EP1273298A2 (en)	2003-01-08
HK1049103A1 (en)	2003-05-02
EP1210941A3 (en)	2002-07-31
DK0871465T3 (da)	2003-02-03
HK1053782A1 (en)	2003-11-07

Publication	Publication Date	Title
DK0871465T3 (da)	2003-02-03	Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS
DE60036961D1 (de)	2007-12-13	Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
NL300385I1 (nl)	2009-07-01	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases.
MXPA04006553A (es)	2004-10-04	Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.
TW200602350A (en)	2006-01-16	Methods and compositions for treating hepatitis C virus
MY138860A (en)	2009-08-28	Hiv protease inhibitors.
ES2141957T3 (es)	2000-04-01	Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
ATE215952T1 (de)	2002-04-15	Hiv-proteaseinhibitoren
HRP20050557A2 (en)	2006-05-31	Method for improving the pharmacokinetics of a nnrti
ZA991029B (en)	1999-09-30	Composition and methods for treatment of hiv infections.
DE60128100D1 (de)	2007-06-06	Analgetisches arzneimittel
FI973184A7 (fi)	1997-09-30	Kombinaatioterapia HIV-infektiota varten käyttäen HIV-proteaasi-inhibi ittoria indinavir ja käänteistranskriptaasi-inhibiittoria 3TC, mahdoll isesti yhdessä AZT:n, DDI:n tai DDC:n kanssa
WO2001014576A8 (en)	2002-06-20	Process and intermediates for the preparation of isoxazolecaroxamides and analogues
WO1996000068A3 (en)	1996-02-22	Combination therapy for hiv infection
NO20002481L (no)	2000-07-12	Kombinasjonsterapi for behandling av AIDS
EP0774969B8 (en)	2003-07-02	Hiv protease inhibitor combination
EP1549642A4 (en)	2006-09-20	6-METHYLPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING THEM
FI970565A0 (fi)	1997-02-10	HIV-proteaasia inhiboiva yhdistelmä
SE9900438D0 (sv)	1999-02-10	The pharmacological use of certian cystine derivatives